With Bayer facing thousands of lawsuits by women who suffered blood clot injuries after taking the birth control Yaz or Yasmin, the company announced last year that they would begin settling many of the cases.
However, until the latest financial reports were released last week, patients had no idea how much had been spent to date or whether the settlements would continue.
DrugRisk has now uncovered Bayer’s 2012 annual report, which states the company has spent around $1 billion through mid-February to settle approximately 4,800 Yaz lawsuits, and will continue to evaluate new claims on a case-by-case basis.
Experts from the British Medical Journal, FDA and New England journal of Medicine have all advised that birth control pills with the hormone drospirenone, like Yaz and Yasmin, can increase the risk of blood clots, DVT and pulmonary embolism by over 70%.
France recently announced they would no longer reimburse women for the cost of the drug due to health concerns.
Although Yaz remains available in the United States, so many women have filed a Yaz lawsuit that the cases were consolidated in a special federal Multi-District Litigation court in Illinois. Bayer’s latest report admits the drug maker faces injury claims from as many as 13,600 people.*
The news that Bayer will continue to evaluate blood clot claims is positive news for anyone who has suffered a blood clot injury but has not yet filed a claim. However, the time to file is still limited.
Anyone who suffered a blood clot, DVT, stroke or Pulmonary Embolism after taking Yaz or Yasmin is urged to speak with a lawyer about their legal options as soon as possible.
Due to the specialized nature of the federal drug injury claims, DrugRisk cautions that patients should seek a lawyer with experience in defective drug litigation, and only recommends lawyers and law firms who have already settled Yaz lawsuits.
Contact us today for more information on the research, side effects and litigation news related to Yaz, or to speak with a lawyer.
*Bayer 2012 Annual Report, Consolidated Financial Statement, Legal Notes, February 28, 2013